secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2024-10-07T23:59:59+00:00
Accession:  0001558370-24-013167
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.03, 2.01, 3.02, 3.03, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virios acquires Pharmagesic, receives $19.5M loan, appoints new board, changes name to Dogwood Therapeutics
--------------------------------------------------------------------------------

- Acquired 100% of Pharmagesic from Sealbond; issued 211,383 common shares and ~2,108 Series A convertible preferred shares.
- Received $19.5M loan from CKLS affiliate; $16.5M funded at close, $3M due Feb 2025.
- Existing shareholders get CVR entitling to 87.75% of future Halneuron milestone payments over 7 years.
- Board: Richard Burch resigned; Alan Yu and Melvin Toh (CKLS) appointed; Angela Walsh promoted to CFO.
- Name change to Dogwood Therapeutics; stockholder meeting required for conversion and reverse split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024013167/0001558370-24-013167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024013167/viri-20241004x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-013167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer